Harvest Technologies’ case in the U.S. District Court in Massachusetts is proceeding to trial November 29th on the issue of the invalidity of Cytomedix, Inc’s U.S. Patent No. 5,165,938

Harvest Technologies’ case in the U.S. District Court in Massachusetts is proceeding to trial on the issue of the invalidity of Cytomedix, Inc’s U.S. Patent No. 5,165,938 (the Knighton Patent). On September 9, 2004, the court interpreted the meaning of the Knighton Patent claims with the issue of patent invalidity to be heard at trial on November 29, 2004.

Harvest believes the court’s ruling to be favorable to its position that the Knighton patent is invalid and remains confident that it will prevail in this case. Harvest further believes that the Knighton Patent is invalid because the prior art, including prior issued patents and other printed publications, teaches the process claimed in the Knighton Patent.

“This ruling now focuses our efforts on exposing the prior art which we expect the courts to clearly recognize and to invalidate the Knighton patent and stop Cytomedix’s efforts at going after Harvest and other manufacturers and especially our customers, the end-users of this important clinical therapy” said Gary Tureski, President, Harvest Technologies Corp. 

For more information contact:

Harvest Technologies Corporation
40 Grissom Road
Suite 100
Plymouth, MA 02360
Tel: 508-732-7500
Fax: 508-732-0400
Email: [email protected]